Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis REPLY

被引：0
|
作者：
Sands, Bruce E. [1 ]
Schreiber, Stefan [2 ]
Lirio, Richard A. [3 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Univ Hosp Schleswig Holstein, Kiel, Germany
[3] Takeda Dev Ctr Amer, Cambridge, MA USA
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 382卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：93 / 94
页数：2
相关论文
共 50 条
  • [1] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    Sands, Bruce E.
    Peyrin-Biroulet, Laurent
    Loftus, Edward V., Jr.
    Danese, Silvio
    Colombel, Jean-Frederic
    Toruner, Murat
    Jonaitis, Laimas
    Abhyankar, Brihad
    Chen, Jingjing
    Rogers, Raquel
    Lirio, Richard A.
    Bornstein, Jeffrey D.
    Schreiber, Stefan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (13): : 1215 - 1226
  • [2] Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis
    Tribich, Samuel
    Maurice, James
    [J]. FRONTLINE GASTROENTEROLOGY, 2020, 11 (02) : 173 - 173
  • [3] Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
    O'Connor, Donal B.
    Lahiff, Conor
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (01): : 92 - 93
  • [4] Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
    Feagan, Brian G.
    Schreiber, Stefan
    Wolf, Douglas C.
    Axler, Jeffrey L.
    Kaviya, Arpeat
    James, Alexandra
    Curtis, Rebecca I.
    Geransar, Parnia
    Stallmach, Andreas
    Ehehalt, Robert
    Bokemeyer, Bernd
    Khalid, Javaria Mona
    O'Byrne, Sharon
    [J]. INFLAMMATORY BOWEL DISEASES, 2019, 25 (06) : 1028 - 1035
  • [5] Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
    Yokomizo, Lauren
    Limketkai, Berkeley
    Park, K. T.
    [J]. BMJ OPEN GASTROENTEROLOGY, 2016, 3 (01):
  • [6] COST-EFFECTIVENESS OF VEDOLIZUMAB FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS IN THAILAND
    Sruamsiri, R.
    [J]. VALUE IN HEALTH, 2018, 21 : S2 - S2
  • [7] Economic evaluation of vedolizumab SC for the treatment of moderate-to-severe ulcerative colitis in Canada
    Fischer, A.
    Oppe, M.
    Stypa, S.
    Lukyanov, V.
    Petrakis, I.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S387 - S387
  • [8] The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis
    Shahidi, Neal
    Bressler, Brian
    Panaccione, Remo
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (03) : 330 - 338
  • [9] Induction and Maintenance of Clinical Remission by Adalimumab in Patients With Moderate-to-Severe Ulcerative Colitis
    Sandborn, William J.
    Van Assche, Gert A.
    Reinisch, Walter
    Colombel, Jean-Frederic
    D'Haens, Geert R.
    Wolf, Douglas C.
    Kron, Martina
    Tighe, Mary Beth
    Lazar, Andreas
    Thakkar, Roopal
    [J]. GASTROENTEROLOGY, 2011, 140 (05) : S123 - S124
  • [10] Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
    Warner, Ben
    Harris, Adam W.
    [J]. GASTROENTEROLOGY, 2012, 143 (01) : E42 - E42
12345